drugset / Trial / NCT02343744
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to examine descriptively the efficacy of CNTO 1959 in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
Timeline
- Start
- 2015-01-19
- Primary completion
- 2015-12-04
- Completion
- 2018-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Guselkumab | Monoclonal antibody | 50 mg | Subcutaneous |
| Subject | Guselkumab | Monoclonal antibody | 100 mg | Subcutaneous |